4:21 PM Abstract No. 246 Transarterial Y90 radioembolization of liver metastases from breast cancer

Abstract

To evaluate safety and efficacy of transarterial hepatic Y90 radioembolization in patients with breast cancer liver metastases. From September 2011 to May 2018, 22 female patients with liver metastases from breast cancer and median age of 63 years (range, 31-71 years), were treated with transarterial hepatic Yttrium-90 glass microsphere radioembolization. Retrospective review of medical records and imaging studies was performed to evaluate toxicities, progression free survival, and overall survival. All patients had received prior systemic chemotherapy. The median follow-up period from radioembolization was 393 days (range, 113-1340 days). 15 patients had right lobar treatment, 4 had left lobar, 2 had segmental and 1 patient had whole-liver treatment. Survival data was analyzed by Kaplan-Meyer method. Multivariate analysis was used to compare Albumin-Bilirubin (ALBI) score, Model for end-stage liver disease (MELD) score, total bilirubin, serum albumin, alkaline phosphatase, and Ca15-3 before and at 1-month post radioembolization. Log-rank test was used to compare outcomes by factors. Common Terminology Criteria for Adverse Events (CTCAE) was used to report and grade adverse events. From the date of radioembolization, median overall survival was 13 months (95%CI, 8.6 -17.5 months), median hepatic progression free survival was 7-months (95%CI, 4.4-9.7 months) and median overall progression free survival was 3 months (95%CI, 0.7-5 months). There was no significant change in ALBI score (P = 0.74), MELD score (P = 0.619), total bilirubin (P = 0.891), serum albumin (P = 0.678), alkaline phosphatase (P = 0.928) and Ca15-3 (P = 0.222) at 1 month posttreatment. Overall survival was higher for patients with right lobar treatment (13 months) than left lobar (6 months) treatment (P = 0.08). Only 2 patients had a CTCAE of 3 after the procedure, and 20 patients had a CTCAE < 3. Transarterial Y90 radioembolization of liver metastases from breast cancer is a safe procedure with an efficacy comparable to the efficacy of transarterial chemoembolization found in literature. Limitations of the study include its retrospective nature and the low patient number.